Teratoma screening: Difference between revisions
| Line 18: | Line 18: | ||
Based on fair evidence, screening for testicular cancer would not result in an appreciable decrease in mortality, in part because therapy at each stage is so effective. | Based on fair evidence, screening for testicular cancer would not result in an appreciable decrease in mortality, in part because therapy at each stage is so effective. | ||
screening would result in unnecessary diagnostic procedures with attendant morbidity. | screening would result in unnecessary diagnostic procedures with attendant morbidity.<ref name="urlTesticular Cancer Screening (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK65967/ |title=Testicular Cancer Screening (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf |format= |work= |accessdate=}}</ref> | ||
==References== | ==References== | ||
Revision as of 19:00, 26 August 2019
|
Teratoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Teratoma screening On the Web |
|
American Roentgen Ray Society Images of Teratoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
There is insufficient evidence to recommend routine screening for Teratoma.
Based on fair evidence, screening for testicular cancer would not result in an appreciable decrease in mortality, in part because therapy at each stage is so effective.
screening would result in unnecessary diagnostic procedures with attendant morbidity.[1]